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A Population Pharmacokinetic Model
Incorporating Saturable Pharmacokinetics
and Autoinduction for High Rifampicin Doses
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Stephen H. Gillespie5, Martin J. Boeree6 and Ulrika S.H. Simonsson1
Accumulating evidence suggests that increasing doses of rifampicin may shorten tuberculosis treatment. The PanACEA
HIGHRIF1 trial assessed safety, pharmacokinetics, and antimycobacterial activity of rifampicin at doses up to 40mg/kg.
Eighty-three pulmonary tuberculosis patients received 10, 20, 25, 30, 35, or 40mg/kg rifampicin daily over 2 weeks,
supplemented with standard doses of isoniazid, pyrazinamide, and ethambutol in the second week. This study aimed at
characterizing rifampicin pharmacokinetics observed in HIGHRIF1 using nonlinearmixed effects modeling. The final
population pharmacokinetic model included an enzyme turnovermodel accounting for time-dependent elimination due to
autoinduction, concentration-dependent clearance, and dose-dependent bioavailability. The relationship between clearance
and concentration was characterized by a Michaelis–Menten relationship. The relationship between bioavailability and
dose was described using an Emax relationship. The model will be key in determining exposure–response relationships for
rifampicin and should be considered when designing future trials and when treating future patients with high-dose
rifampicin.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 The dose- and time-dependent pharmacokinetics of rifampi-
cin have been studied since its introduction to the market in
1971 based on the recommended dose of 10 mg/kg.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The study describes the population pharmacokinetic charac-
teristics of rifampicin given in doses of up to 40 mg/kg.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 This is the ﬁrst population pharmacokinetic model describ-
ing rifampicin pharmacokinetics after doses up to 40 mg/kg. It
is also the ﬁrst evidence suggesting a dose-dependent increase in
bioavailability for rifampicin.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 The presented model will enable prediction of rifampicin
plasma concentrations at doses up to 40 mg/kg. It will aid in
deciding the future dose of rifampicin since it allows for clini-
cal trial simulation and can be used as input to exposure–
response analyses. Furthermore, the model can be used to
improve therapeutic drug monitoring with higher doses of
rifampicin.
Rifampicin is a cornerstone in the treatment of pulmonary tuber-
culosis (TB) and reduced treatment time from 12 to 9 months
by its introduction to the market in 1971.1 The currently recom-
mended dose of the antibiotic is 10 mg/kg administered daily.2
The rationale for selecting 10 mg/kg was not achieved through
current dose selection standards3 and accumulating data suggest
that increasing the dose might reduce treatment time further.4,5
The PanACEA HIGHRIF1 trial was performed to study
short-term safety, pharmacokinetics (PK), and antimycobacterial
activity of higher doses of rifampicin.6 Up to 35 mg/kg of daily
rifampicin was safe and an unprecedented increase in exposure
was seen where the average total exposure at 35 mg/kg was almost
10 times higher than for 10 mg/kg. This more than linear
increase in exposure was accompanied by a decrease in exposure
with time. A higher dose of 40 mg/kg was studied in the mean-
time and was also safe.
The nonlinear increase in exposure of rifampicin with dose has
been known since the early 1970s7 and was described in the ﬁrst
clinical trial that evaluated the concept of high-dose rifampicin
more recently.8 Reported reasons for the nonlinear increase in
1Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden; 2Department of Pharmacy, Radboud University Medical Center, Nijmegen,
the Netherlands; 3DST/NRF Centre of Excellence for Biomedical Tuberculosis Research and MRC Centre for TB Research, Division of Molecular Biology and
Human Genetics, Stellenbosch University, Tygerberg, South Africa and TASK Applied Sciences, Cape Town, South Africa; 4Department of Respiratory Medicine,
University of Cape Town, Cape Town, South Africa and The Lung Institute, Cape Town, South Africa; 5School of Medicine, University of St. Andrews, St. Andrews
Fife, UK; 6Department of Lung Diseases, Radboud University Medical Center, Nijmegen, the Netherlands and University Centre for Chronic Diseases
Dekkerswald, Groesbeek, the Netherlands. Correspondence: U.S.H. Simonsson (ulrika.simonsson@farmbio.uu.se)
Received 27 March 2017; accepted 16 June 2017; advance online publication 00 Month 2017. doi:10.1002/cpt.778
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 00 NUMBER 00 | MONTH 2017 1
ARTICLES
exposure include saturable biliary excretion7,9 as well as an
exposure-dependent bioavailability (F).10 The decrease in rifampi-
cin exposure with time is due to increased elimination by induction
of enzymes and/or transporters caused by the antibiotic itself,
referred to as autoinduction.9 Rifampicin activates the nuclear preg-
nane X receptor (PXR), which leads to increased gene transcription
of several systemic and presystemic metabolizing enzymes and drug
transporters.11
There are already several population PK models for rifampicin,
including models that do not include any structural nonlinearity
in PK parameters,12,13 a model including structural components
describing autoinduction,14 and a model including structural compo-
nents for autoinduction and a nonlinear increase in exposure.10 All
of these were based on the 10 mg/kg rifampicin dose. Thus, this is
the ﬁrst population PK analysis exploring high-dose rifampicin with
the objective of characterizing the nonlinear dose–exposure relation-
ship and autoinduction following higher doses of rifampicin.
RESULTS
Model development was performed using rifampicin plasma
concentrations from the 83 patients in the HIGHRIF1 trial,6 as
summarized in Table 1. No data points were excluded on day 7,
where every patient contributed 11 samples, which resulted in
913 samples. On day 14, 46 samples were excluded, as described
in Supplementary Appendix S1. Of the 1,780 analyzed data
points, 13.6% were below the limit of quantiﬁcation (LOQ).
Structural model
The autoinduction, evident as a decrease in exposure from day 7
to 14, was accounted for using a previously developed enzyme
turnover model for rifampicin14 without structural modiﬁcation
(Figure 1). The parameters were ﬁxed to the previously reported
estimates14 during early model development but were reestimated
at a later stage, which gave a 100-point drop in the objective
function value (OFV). The parameter kENZ was estimated to
0.00603 h-1, corresponding to a half-life of 4.79 days. The typical
predicted increase in apparent clearance (CL/F) for all dose
groups between days 0 and 14 are shown in Figure 2a for the
median patient in the dataset (weighing 53.9 kg and a fat-free
mass (FFM) of 44.6 kg).
The nonlinear increase in exposure seen at the higher doses was
accounted for by a concentration-dependent CL/F and a dose-
dependent relative F. The CL/F was described by the following
equation:
CL=FðCpÞ5
Vmax
km1Cp
where Vmax is the maximal elimination rate and km is the rifampicin
plasma concentration (Cp) at which the elimination is half-maximal.
Introducing a nonlinear CL/F in the model decreased the OFV by
92.9 points compared to having linear CL/F. The typical predicted
relationship between CL/F and Cp at the preinduced state for the
median patient is shown in Figure 2b. Dividing total CL/F into
two parallel elimination pathways (linear 1 nonlinear) gave a
decreased OFV by 10.2 points. However, when the signiﬁcant dose-
dependency in F was introduced into the model (see below), there
was no longer any improvement in OFV upon inclusion of two
elimination pathways. Hence, the ﬁnal model only included one
elimination pathway.
The statistically signiﬁcant relationship between dose and F
was described using an Emax relationship according to:
F5F4503 11
Fmax3ðDose2450Þ
ED501ðDose2450Þ
 
where F450 is F for 450 mg, assumed to be 1. Parameters Fmax
and ED50 are the maximal increase in F and the dose above
450 mg that corresponds to half the Fmax, respectively. Inclusion
of the proposed relationship reduced OFV by 28.2 points. The
ED50 was estimated to 67.0 mg, corresponding to a dose of
517 mg. The predicted relationship between F and dose is shown
in Figure 2c.
The distribution of rifampicin was best described using the
one-compartment disposition model. Absorption was best
described by an absorption transit compartment model.
Stochastic model
The residual error model included a normally distributed additive
error on log-scale, which approximates to a constant coefﬁcient of
variance on normal scale. Interindividual variability (IIV) in km,
apparent volume of distribution (V/F), mean transit time (MTT),
number of transits (NN), absorption rate constant (ka), and Vmax
was statistically signiﬁcant, as well as interoccasion variability (IOV)
in F, MTT, km, and ka. Covariance was statistically signiﬁcant
between Vmax and km. Other covariances were statistically signiﬁ-
cant, but when attempts were made to include more than one
covariance simultaneously, the model became too unstable, termi-
nated without minimization, and was not able to report any signiﬁ-
cant digits. A similar situation arose when IIV in kENZ was
evaluated where OFV decreased by 9.91 points, but when covariance
was explored using this model, it terminated without minimization.
Hence, IIV in kENZ was excluded due to model stability issues.
Covariate model
The parameters CL/F and V/F were allometrically scaled using
FFM. Sex, race, and age were not identiﬁed as inﬂuential covari-
ates according to stratiﬁed visual predictive checks (VPCs)
performed using the ﬁnal model, stratiﬁed for different values, or
categories for each covariate (results not shown).
Final model
The NONMEM code for the ﬁnal model is given in the Supple-
mentary Material S2. The structure of the ﬁnal model is schemati-
cally represented in Figure 1 and with ﬁnal parameter estimates
shown in Table 2.
Model evaluation
The ﬁnal model described the observed continuous data and the
observed proportions of samples below the LOQ well in all dose
groups according to a VPC (Figure 3). Figure 4 shows posterior
predictive checks performed using the ﬁnal model for the
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noncompartmental analysis (NCA) metrics including the highest
observed plasma concentration (Cmax) and the area under
the plasma concentration–time curve between 0 and 24 h
(AUC0-24h). Both Cmax and AUC0-24h were overall predicted
well across all dose groups.
Clinical trial simulation
The clinical trial simulations show that AUC0-24h at day 14
increased more than proportionally compared to 10 mg/kg for all
dose groups (Table 3). The 90% prediction intervals overlapped
with the median values for a lower and/or higher dose group for
the 30, 35, and 40 mg/kg dose groups.
DISCUSSION
We present a population PK model based on clinical observations
that includes doses of rifampicin up to 40 mg/kg. It includes com-
ponents describing concentration- and time-dependent elimination
as well as a dose-dependency in bioavailability. Our ﬁnal model
predicted the continuous concentrations and proportions of data
below LOQ well across all dose arms at days 7 and 14. The model
was able to predict the commonly used NCA (i.e., nonmodel-
based) metrics Cmax and AUC0-24h. The results of this study
allows for reliable predictions of rifampicin exposures at doses up
to 40 mg/kg.
The capacity-limited elimination and dose-dependency in F
may cause overexposure at higher doses, which may create safety
issues. In contrast, the time-dependent elimination leads to lower
exposures over time that can lead to suboptimal treatment.
Without a model taking these phenomena into account simulta-
neously, the exposures will be highly unpredictable.
The model predicted 1.73, 1.89, 1.91, 1.94, 1.97, and 1.99-fold
increases in CL/F for the 10, 20, 25, 30, 35, and 40 mg/kg dose
groups, respectively, at steady state compared to a single dose. Pre-
vious models predicted increases of 1.8514 and 1.8910 for the
10 mg/kg dose. The predicted half-life for the autoinduction was
4.79 days, which agrees well with the estimate from Chirehwa
et al.10 of 4.5 days but is shorter than the estimate reported by
Smythe et al.14 of 7.83 days. The former is probably more reli-
able, since it includes multiple PK sampling occasions between
days 1 and 29, whereas the latter only includes data at days 0 and
28. A half-life of 4.79 days for the autoinduction phenomenon
Figure 1 Schematic representation of the final rifampicin population
pharmacokinetic model. The dose (Dose) goes into the absorption com-
partment (Abs) via a transit compartment model (Transit), where NN
describes the number of transit compartments and the transfer rate
between transit compartments described by the transit rate constant (ktr),
calculated as the NN11 divided by the mean transit time (MTT). The frac-
tion of drug that reaches Abs is dose-dependent and increases at higher
doses. The drug is absorbed from Abs to the central compartment (indi-
cated by Cp, the plasma concentration of rifampicin) described by the
absorption rate constant (ka). The formation of enzyme is described by the
first-order enzyme degradation rate (kENZ, which also serves as the zero-
order formation rate of enzyme using this parameterization) but also stimu-
lated by the presence of drug via an Emax model. The elimination of drug is
described by Michaelis–Menten kinetics, which is increased proportional
to AENZ. F450, relative bioavailability for 450 mg; Fmax, maximal increase in
relative bioavailability; ED50, dose corresponding to half the Fmax; Emax,
maximal increase in enzyme formation rate; EC50, concentration corre-
sponding to 50% of Emax; Vmax, the maximal elimination rate; km, the Cp at
which the elimination is half-maximal; V, volume of distribution.
Figure 2 Typical model predictions from the final rifampicin population
pharmacokinetic model of (a) relative increase in apparent clearance
(CL/F) vs. time for a 53.9 kg patient for the different dose groups, (b) CL/F
vs. rifampicin plasma concentration, and (c) relative increase in
bioavailability (F) vs. rifampicin dose.
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implies that it takes 24 days (5 half-lives) to reach the fully
induced state of rifampicin autoinduction.
The current rifampicin dataset would probably not allow for
full characterization of the nonlinear time-dependency in CL/F.
But by assuming the same structure as a previous enzyme turn-
over model for rifampicin14 it was possible to characterize the
autoinduction and distinguish it from the capacity-limited
elimination.
The presented model suggests capacity-limited elimination of
rifampicin, which coincides with a previous NCA report7 and a
population PK model.10 Rifampicin is eliminated through active
secretion into the bile, which is known to be saturable.9 The
transporter responsible for the active secretion is unknown. The
maximum predicted typical CL/F at the preinduced state was
14.9 L/h/70 kg (i.e., at 0 mg/L, Figure 2b), 3.44 times higher
than the typical CL/F for a concentration of, e.g., 85.8 mg/L
(highest observed rifampicin concentration in the dataset). A pre-
vious model-based estimate of km is 3.35 mg/L,
10 which is mark-
edly lower than our estimate of 35.3 mg/L. The discrepancy
between these estimates may exist because in contrast to the
model presented here, Chirehwa et al.10 assumed a well-stirred
liver model and do not include doses above 10 mg/kg.
The ﬁnal model included a dose-dependent F, suggesting a
maximal increase of 50.4% where half of the maximum increase
occurs at 517 mg. There is a lack of intravenous (i.v.) vs. oral data
to fully support this ﬁnding. Loos et al.15 compared 600 mg of
daily i.v. and oral rifampicin during 3 weeks. Rifampicin F
decreased from 90–100% at day 1 to 70% after 1 and 3 weeks.
Table 2 Parameter estimates from the final rifampicin population pharmacokinetic model
Parameter Description Estimate 90% CIa
Vmax (mg/h/70 kg) Maximal elimination rate 525 430–564
km (mg/L) Rifampicin concentration at which
the elimination is half-maximal
35.3 29.9–39.1
V (L/70 kg) Volume of distribution 87.2 83.1–95.4
ka (h
-1) Absorption rate constant 1.77 1.50–1.92
MTT (h) Mean transit time 0.513 0.478–0.613
NN Number of transits 23.8 20.6–26.4
Emax Maximal increase in enzyme
production rate
1.16 1.14–1.17
EC50 (mg/L) Rifampicin concentration at which
half the Emax is reached
0.0699 0.0523–0.0761
kENZ (h
-1) First-order rate constant for enzyme
pool degradation
0.00603 0.00587–0.00622
Fmax Maximal increase in relative bioavailability
above 450 mg
0.504 0.429–0.574
ED50 (mg) Difference in rifampicin dose from
450 mg at which half the Fmax is reached
67.0 57.1–80.5
IIV Vmax (%)
b 30.0 24.7–40.9
IIV km (%)
b 35.8 30.1–42.5
IIV V (%)b 7.86 6.98–9.17
IIV ka (%)
b 33.8 30.1–38.4
IIV MTT (%)b 38.2 34.7–44.7
IIV NN (%)b 77.9 71.8–88.9
IOV km (%)
c 18.9 16.7–21.7
IOV ka (%)
c 31.4 27.7–36.9
IOV MTT (%)c 56.4 48.8–62.6
IOV F (%)c 15.7 13.4–18.0
Correlation Vmax-km (%) 38.9 4.34–72.2
‹ (%) Additive error on log scale 23.6 19.3–26.4
CI, confidence interval; IIV, interindividual variability; IOV, interoccasion variability.
a90% CI is the 90% percentile confidence interval from a nonparametric bootstrap (1,000 samples). bInterindividual variability expressed as coefficient of variation and in
% of the parameter estimate. cInteroccasion variability expressed as coefficient of variation and in % of the parameter estimate.
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Figure 3 Visual predictive check for the observed rifampicin concentrations stratified on dose group and day where a–f show the day 7 observations for
10, 20, 25, 30, 35, and 40 mg/kg rifampicin, respectively, and g–l show the day 14 observations for 10, 20, 25, 30, 35, and 40 mg/kg rifampicin,
respectively. Open circles are the observations. The upper and lower dashed lines are the 95th and 5th percentiles of the observed data, respectively,
and the solid line is the median of the observed data. The shaded areas (top to bottom) are the 95% confidence intervals of the 95th (light gray), median
(dark gray), and 5th (light gray) percentiles of the simulated data based on 1,000 simulations. The lower limit of quantification (indicated as LLOQ) panels
show the observed proportions of samples below the limit of quantification (BLOQ) as open circles and the 95% confidence interval of the simulated
proportion as a shaded gray area.
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Thus, a time-dependency was seen in F, which was attributed to
autoinduction of nonhepatic presystemic elimination. No time-
dependency in F was explored in our study because the reported
increase in F reached a maximum after 1 week15 and our dataset
included observations on days 7 and 14. Loos et al.15 did not
observe any dose-dependency (since only one dose was included)
and with no similar studies available, our analysis is the ﬁrst evi-
dence suggesting a dose-dependency in F as attributed to satura-
tion of nonhepatic presystemic elimination at high doses of
rifampicin. At 10 mg/kg rifampicin, gut wall enzymes and/or
transporters suppress the bioavailability of rifampicin, but at
higher rifampicin doses the enzymes and/or transporters become
saturated. The speciﬁc enzymes and/or transporters is unknown
but may involve CYP3A4 and/or P-glycoprotein.16
A previous PK model for rifampicin10 includes exposure-
dependency in F, but this is attributed to saturation of hepatic
ﬁrst-pass elimination, as described using the well-stirred liver
model. This model was not tested on our dataset, partly because
it contrasts the ﬁndings of Loos et al.15 that hepatic ﬁrst-pass
elimination is not a likely cause of the reduced F of 70% for
10 mg/kg,9 as the hepatic extraction ratio of rifampicin was clas-
siﬁed as low (0–10%),15 which is also in agreement with the
interpretation by Kenny and Strates in 1981.17 No other evi-
dence using as robust a methodology exists that can conﬁrm the
hepatic extraction ratio of rifampicin. Conﬁrmation of the ﬁnd-
ings require a very rich study including blood and plasma
Figure 4 Posterior predictive checks for the noncompartmental analysis (NCA)-based metrics including the highest observed plasma concentration
(Cmax) in (a) and the area under the plasma concentration–time-curve between 0 and 24 hours (AUC0-24h) in (b) for the different dose groups. The upper
and lower dashed lines and the solid lines are the upper range, lower range, and median, respectively, of the NCA metrics calculated from the observed
dataset. The upper and lower light gray and the dark gray shaded areas are the 95% confidence intervals of the simulated upper range, lower range, and
median, respectively, calculated from 1,000 simulated datasets.
Table 3 Predicted increase in exposure at day 14 compared to
10 mg/kg rifampicin
Dose group (mg/kg)
Predicted increase in median
AUC0-24h at day 14 (%)
Median 90% prediction interval
20 239 152–343
25 330 230–460
30 525 370–708
35 667 479–914
40 760 549–1040
AUC0-24h, area under the plasma concentration–time curve between 0 and 24 h.
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measurements and urine collection following i.v. and oral doses,
preferably for several rifampicin doses.
Rifampicin was assumed to be eliminated by a single elimina-
tion pathway (Figure 1). Reports on the elimination of rifampi-
cin propose two relevant processes: metabolic transformation
into desacetylrifampicin (main metabolite), and biliary excretion.
The former is likely the major contributor to the elimination of
rifampicin,18,19 whereas the latter is likely to be a saturable pro-
cess.7,9 Therefore, we tested a model including two parallel (linear
and nonlinear) elimination pathways. No literature data to our
knowledge supports concentration-dependency in the metabolic
pathway, which would represent the linear elimination pathway
and the biliary excretion would represent the nonlinear pathway.
However, no model including more than one pathway was
supported by the data.
Mechanistically, a model including more than one elimination
pathway appears plausible, but even such a model would likely
not represent the complete picture. First, describing elimination
only based on hepatic elimination is theoretically wrong, since a
nonnegligible fraction of rifampicin is eliminated renally.9 Sec-
ond, the parent drug and the main metabolite are both cleared
via biliary excretion9 and there may therefore be an intricate
dependence between the elimination pathways. The ﬁnal model
is not intended to be viewed as the mechanistically most correct
model, but a model able to describe the complex data including
relatively few model parameters. The elimination of rifampicin is
complex and in order to further characterize it, data including
i.v., urine, and metabolite data and data from even higher doses
of rifampicin may be relevant.
The PK of rifampicin was assumed to be unaffected by coad-
ministration of isoniazid, pyrazinamide, and ethambutol. There
are no data available to support any clinically signiﬁcant changes
of rifampicin PK by isoniazid, pyrazinamide, and ethambutol.20
In addition, as rifampicin PK is time-dependent (autoinduction),
interactions would probably have been unidentiﬁable using the
current dataset.
Rifampicin is predicted to be a key component of future treat-
ment regimens against TB, likely at a dose higher than 10 mg/kg.21
Thus, many patients will be treated with higher doses of rifampicin.
Our model allows for better control of the exposure of rifampicin
by forecasting the individual exposures of higher doses using thera-
peutic drug monitoring (TDM), a growing ﬁeld for TB and rifamy-
cins.22 Furthermore, the main interest is often the exposure at full
autoinduction, whereas PK sampling is often performed before full
induction has been reached, which can introduce bias. The model
can aid in such situations by predicting the exposure at full induc-
tion based on early PK samples.
The model can be used to evaluate trial designs of future PK
studies. The current study included many samples. Future trials
may face stricter ﬁnancial or ethical concerns that require sparser
sampling and investigators must decide which sample(s) to omit
from the protocol. Our model can be used to explore designs
including fewer samples by simulating designs with different
sampling schemes and evaluate if relevant metrics (e.g., AUC0-
24h) can be estimated with acceptable precision and accuracy with
reduced designs.
The results may further be used to make unbiased exposure–
response evaluations, regarding both safety and efﬁcacy. Markers
for safety and/or efﬁcacy are usually collected at different time-
points compared to PK samples. With time-dependent PK there
is a risk of biasing exposure–response relationships if the exposure
at, e.g., day 7 are used to describe exposure–response at steady
state. The model can account for such time-dependent exposures.
For the model presented here, PK predictions following even
higher doses of rifampicin would aid in the design of trials with
these doses and are therefore relevant. But this poses a problem,
since only one elimination pathway is included in the ﬁnal model,
which may not be mechanistically correct. An attribute of less
mechanistic models is that prediction outside the range of the
observed data requires careful consideration.23,24 The asymptotic
consequence of having only one saturable elimination pathway is
that CL/F will approach a value of 0 at high concentrations,
whereas in reality we postulate that a different elimination path-
way takes over at a certain threshold. Therefore, predictions of
exposures at doses above 40 mg/kg using the presented model
should be interpreted carefully.
The developed rifampicin population PK model simulta-
neously accounted for exposure-dependent autoinduction and
nonlinear decrease in CL/F at higher doses of rifampicin. These
ﬁndings will be important when determining rifampicin
exposure–response relationships at the higher doses and should
be taken into consideration when designing future clinical trials
and when performing TDM with higher doses of rifampicin.
The model allows for clinical trial simulations and as input for
future pharmacokinetic-pharmacodynamic modeling in order to
optimize the rifampicin dose.
METHODS
Patients and study design
The data consisted of rifampicin PK data collected in the PanACEA
HIGHRIF 1 trial, an open-label phase II multiple dose-rising trial regis-
tered at www.clinicaltrials.gov (NCT01392911). Prior to conducting the
trial the study protocol was approved by local Ethical Review Boards and
by the Medical Control Council of South Africa and was conducted
according to Good Clinical Practice standards. All patients provided
written informed consent before enrollment in the study. The trial
included 83 adult pulmonary TB patients enrolled in Cape Town, South
Africa. The patients were recruited into six consecutive cohorts where
patients received 10 (n 5 8, reference arm), 20, 25, 30, 35, or 40 (n 5
15/arm) mg/kg daily oral rifampicin for 14 days, with an interim safety
review between the subsequent treatment groups. During the ﬁrst 7 days
rifampicin was given as monotherapy and for the next 7 days supple-
mented with isoniazid, pyrazinamide, and ethambutol. Patients were
sampled for rifampicin total plasma concentrations at 0, 0.5, 1, 1.5, 2, 3,
4, 6, 8, 12, and 24 h on days 7 and 14. More details on the study design
is given in the original publication, which reports on the data up to
35 mg/kg.6
Data analysis
The data were analyzed using log-transformation both sides and the non-
linear mixed effects modeling software NONMEM (v. 7.3; Icon Develop-
ment Solutions, http://www.iconplc.com/technology/products/nonmem,
Ellicott City, MD)25 using Laplacian conditional estimation with interac-
tion. The M3 method26 was used to handle samples below the LOQ of
0.13 mg/L. Data handling and visualization were performed in R (v. 3.2.3;
R Foundation for Statistical Computing, http://www.R-project.org,
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Vienna, Austria).27 Model evaluation was performed by comparing the OFV
using the likelihood ratio test at the 5% signiﬁcance level (decrease in OFV
3.84 between nested models with one added parameter) and diagnostics
generated using Xpose (v. 4.5.3; Department of Pharmaceutical Biosciences,
Uppsala University, http://xpose.sourceforge.net, Uppsala, Sweden)28,29
including VPCs generated using PsN (v 4.5.2; Department of Pharmaceutical
Biosciences, http://psn.sourceforge.net, Uppsala, Sweden)28,30 using 1,000
simulations stratiﬁed on day of treatment and dose group.
Structural model building
Different disposition models were tested including the one- and two-
compartment disposition models. Absorption models were evaluated
including ﬁrst-order absorption with and without lag time and an
absorption transit compartment model.31
An enzyme turnover model for rifampicin14 was used to account for
autoinduction. The change in the amount of inducing enzymes was
described by:
dAENZ
dt
5kENZ3 11
Emax3Cp
EC501Cp
 
2kENZ3AENZ
where AENZ is the relative amount of enzyme, initialized to a value of 1.
The parameter kENZ serves two purposes with the current parameteriza-
tion; it is a ﬁrst-order constant for enzyme degradation and a zero-order
rate for enzyme formation. The Emax is the maximum increase in enzyme
formation and EC50 is the Cp that corresponds to half the Emax. The
AENZ scaled CL/F according to:
CL=FðtÞ5CL=FðCpÞ3AENZ
In order to characterize the nonlinear increase in exposure with increased
rifampicin dose, deviations from linearity were explored in F and CL/F.
For F, models including linear, Emax, or sigmoidal Emax relationships
between F and dose were tested. All models assumed an increase in F at
doses over 450 mg (lowest dose in the dataset). The F was described by
the linear, Emax, and sigmoidal Emax models, respectively, as:
F5F4503ð11slopeF3ðDose2450ÞÞ
F5F4503 11
Fmax3ðDose2450Þ
ED501ðDose2450Þ
 
F5F4503 11
Fmax3ðDose2450Þg
EDg501ðDose2450Þg
 
where slopeF is a dose-dependent linear change in F. The parameter g is
a shape parameter.
For CL/F, nonlinearity was investigated by comparing linearly
decreasing and Michaelis–Menten32 relationships between CL/F and Cp
to the linear model. Additional nonlinear models were tested including
models with two parallel (linear 1 nonlinear) elimination pathways.
Stochastic model building
Different residual error models were explored including additive on log-
scale, additive on the normal scale, and a model including two compo-
nents, one additive on log-scale and one additive on normal scale.
Interindividual variability was investigated in all structural parameters
except slopeF, Fmax, ED50, and g. Interoccasion variability was investi-
gated in all parameters except parameters relating to the autoinduction
and slopeF, Fmax, ED50, and g. Both IIV and IOV were assumed to be
log-normally distributed.
Correlations were investigated for IIVs between absorption parame-
ters (including F) and between parameters relating to elimination
(including autoinduction parameters). Correlations were investigated
also between elimination parameters and V/F.
Covariate model building
Different methods for allometric scaling of CL/F and V/F were explored
using different body size descriptors including total body weight,33–36
FFM,33,37 or an approach where the contributions of each of the two
were estimated.37 The exponents for the allometric relationships were
ﬁxed to 0.75 and 1 for CL/F and V/F, respectively.
The impact of other covariates including age, sex, and race (classiﬁed
as either “black” or “colored”) were assessed graphically by performing
VPCs stratiﬁed on each covariate. Only if model misspeciﬁcation
was evident through our visual investigation was the relevant covariate
relationship evaluated further. The HIV infection covariate was not
investigated since only three patients had HIV infection.
Model evaluation
The ability of the model to predict NCA measures AUC0-24h and Cmax
was assessed by performing a posterior predictive check for days 7 and 14
using ncappc38 within R and PsN. One thousand datasets were simulated
using the ﬁnal model assuming the same study design and covariates as the
original dataset; AUC0-24h and Cmax were calculated from the simulated
datasets, which were then compared with the same metrics calculated
from the observed dataset.
A 1,000 sample bootstrap was performed in PsN28,30 on the ﬁnal
model to obtain the 95% nonparametric conﬁdence interval for all
parameters for assessment of parameter uncertainty.
Clinical trial simulation
Clinical trial simulations were performed using the ﬁnal model to assess
the degree of overlap in the predicted increases in exposure for the differ-
ent dose groups. The increase in median AUC0-24h compared to 10 mg/
kg was calculated for each dose group for 1,000 simulated trials assuming
the same protocol as the HIGHRIF1 trial. Patient covariates were sam-
pled from the dataset used for modeling.
Additional Supporting Information may be found in the online version of
this article.
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